AMAG Reports 2008 Results
For the year ended December 31, 2008, the company’s cash, cash equivalents, investments and settlement rights associated with certain auction rate securities totaled $215.0 million. Revenues for the
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.
The lintuzumab Phase IIb clinical trial is a randomized, double-blind, placebo-controlled study evaluating whether the combination regimen of lintuzumab and low-dose cytarabine chemotherapy extends overall survival compared to